Antibiotic promise in superbug war

June 22, 2018, Flinders University
Dr Ramiz Boulos. Credit: Flinders University

An entirely new class of antibiotics has been shown to be effective against 100 different samples of Clostridium difficile, often the cause of drug-resistant infections picked up by patients while in hospital.

The new antibiotic developed in Australia, called Ramizol, was shown to be effective even against C. difficile which has developed resistant to other currently-available .

A scientific paper published in the journal Diagnostic Microbiology and Infectious Disease (Elsevier), has shown Ramizol, a first-in-class stilbene-based investigational antibiotic for the treatment of Clostridium difficile (CDI), is effective against 100 clinical isolates of C. difficile.

The paper, entitled "Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution," has shown resistance emergence against vancomycin and metronidazole.

The results have shown that vancomycin-resistant isolates are more than 250 times less susceptible (MIC > 8 μg/mL) to fidaxomicin compared to fidaxomin-sensitive strains (MIC90 = 0.03 μg/mL).

The research, which was undertaken jointly by Boulos & Cooper Pharmaceuticals, US-based Micromyx LLC and Flinders University, has shown there is no apparent impact of ribotype, toxin-production, or resistance to fidaxomicin, vancomycin or metronidazole on the activity of Ramizol.

Credit: Flinders University

CEO and founder of Boulos & Cooper Pharmaceuticals, Dr. Ramiz Boulos, says: "C. difficile strains showing resistance to both vancomycin and fidaxomicin is an unexpected finding, given these two antibiotics have different mechanisms of action."

"The emergence of resistance against the only three antibiotics currently used for treating CDI is alarming, highlighting the need for novel, safe and effective antibiotics," he says.

"We believe Ramizol has the potential to be the standard of care for treating CDI and has the potential to be a blockbuster drug," says Dr. Boulos, an adjunct lecturer at the College of Science and Engineering at Flinders University.

Dr. Boulos, who became an SA Tall Poppy of science in 2014 while working on his patented antimicrobials and other projects at the Flinders University Institute of NanoScale Science and Technology in 2013-2014, is now based in Perth where he obtained his Ph.D. in Chemistry from the University of Western Australia in 2011.

Flinders University College of Medicine and Public Health Professor Ross McKinnon and College of Science and Engineering Professor Colin Raston are advisers of Boulos & Cooper Pharmaceuticals.

In the US alone, Dr. Boulos says at least 250,000 people per year are affected by CDI, gonorrhoea and some Gram-negative bacteria every year. With few treatment options and rising antibiotic resistance for these three bacteria, the US Department of Health and Human Services' Centers for Disease Control and Prevention has classified them as "urgent-level" – its highest category of threat level – declaring each of them "an immediate that requires urgent and aggressive attention."

Explore further: New compound shown to be as effective as FDA-approved drugs against life-threatening infections

More information: Cindy Wolfe et al. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution, Diagnostic Microbiology and Infectious Disease (2018). DOI: 10.1016/j.diagmicrobio.2018.06.002

Related Stories

New compound shown to be as effective as FDA-approved drugs against life-threatening infections

June 15, 2018
Purdue University researchers have identified  a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections ...

Metabolite therapy proves effective in treating C. difficile in mice

March 20, 2018
A team of UCLA researchers found that a metabolite therapy was effective in mice for treating a serious infection of the colon known as Clostridium difficile infection, or C. difficile.

Supercharged antibiotics could turn tide against superbugs

January 5, 2018
An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world's most dangerous superbugs.

Can probiotics reduce the severity of C. difficile infections?

August 7, 2014
Probiotics have shown promise for treating patients with recurrent Clostridium difficile infections. However, their safety and quality control requires further study – especially in immunocompromised patients, concludes ...

Researchers define target and mechanism of antibacterial drug fidaxomicin (Dificid)

March 29, 2018
A team of Rutgers University and international scientists has determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid).

Recommended for you

Researchers discover influenza virus doesn't replicate equally in all cells

September 19, 2018
The seasonal flu is caused by different subtypes of Influenza A virus and typically leads to the death of half a million people each year. In order to better understand this virus and how it spreads, University of Minnesota ...

Drugs that stop mosquitoes catching malaria could help eradicate the disease

September 18, 2018
Researchers have identified compounds that could prevent malaria parasites from being able to infect mosquitoes, halting the spread of disease.

Vaccine opt-outs dropped slightly when California added more hurdles

September 18, 2018
In response to spiking rates of parents opting their children out of vaccinations that are required to enroll in school—and just before a huge outbreak of measles at Disneyland in 2014—California passed AB-2109. The law ...

New evidence of a preventative therapy for gout

September 17, 2018
Among patients with cardiovascular disease, it's a common complaint: a sudden, piercing pain, stiffness or tenderness in a joint that lasts for days at a time with all signs pointing to a gout attack. Gout and cardiovascular ...

"Atypical" virus discovered to be driver of certain kidney diseases

September 14, 2018
An international research team led by Wolfgang Weninger has discovered a previously unknown virus that acts as a "driver" for certain kidney diseases (interstitial nephropathy). This "atypical" virus, which the scientists ...

Flu shot rates in clinics drop as day progresses, but nudges help give them a boost

September 14, 2018
Primary care clinics experienced a significant decline in influenza vaccinations as the day progressed, researchers from Penn Medicine report in a new study published in JAMA Open Network. However, "nudging" clinical staff ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.